RGNX Earnings Prediction
The chart below shows how RGNX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RGNX sees a -3.29% change in stock price 10 days leading up to the earnings, and a -1.00% change 10 days following the report. On the earnings day itself, the stock moves by -0.19%. This data can give you a slight idea of what to expect for the next quarter's release.
RGNX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
24.20M
-16.31%
8.53%
Gross Margin
48.81%
-14.61%
-7.12%
Operating Margin
-256.55%
14.19%
2.07%
Net Margin
-246.30%
15.11%
3.63%
EPS
-1.17
-17.02%
11.43%
No Data Available
RGNX Earnings Analysis
REGENXBIO Inc. Corporation (RGNX.O) Earnings Conference Call
Positive
BLA Submission Milestone: 1. Successful BLA Submission: REGENXBIO submitted the first module of a rolling Biologics License Application (BLA) for RGX-121 in Q3 2024, with completion expected in Q1 2025, marking a significant milestone for the company and patients with MPS 2.
Cash Reserves Stability: 2. Strong Cash Position: The company ended Q3 2024 with cash, cash equivalents, and marketable securities of $279 million, which is projected to fund operations into 2026, providing a solid financial foundation for ongoing projects.
RGX-202 Clinical Trial Update: 3. Positive Clinical Data for RGX-202: The RGX-202 program for Duchenne muscular dystrophy has shown a favorable safety profile with no serious adverse events reported, and the company is preparing to initiate a pivotal trial, positioning it as a potential best-in-class therapy.
RGX-314 Efficacy Results: 4. Encouraging Results in RGX-314: In the Phase 2 fellow eye study for RGX-314, 100% of patients required zero or one supplemental injections, demonstrating a 97% reduction in treatment burden at 9 months, indicating strong efficacy and safety.
Patient Cohort Expansion: 5. Expansion of Patient Cohorts: REGENXBIO has successfully dosed the first patient in the new cohort of 1 to 3-year-olds for the RGX-202 trial, addressing a significant unmet need in this age group with no current access to gene therapy options.
Negative
Cash Reserves Decline: 1. Declining Cash Reserves: REGENXBIO's cash, cash equivalents, and marketable securities decreased to $279 million as of September 30, 2024, down from $314 million at the end of 2023, indicating a concerning cash burn rate.
R&D Expense Reduction: 2. Increased R&D Expenses: Research and development expenses were $54 million for Q3 2024, a decrease from $58 million in Q3 2023, suggesting potential cost-cutting measures that may impact future development.
Patient Recruitment Challenges: 3. Limited Patient Cohort: The company is facing challenges in recruiting younger patients (1-3 years) for the Duchenne program, which may hinder the robustness of clinical data due to a small sample size.
Regulatory Approval Challenges: 4. Uncertain Regulatory Path: There is no guarantee of accelerated approval for RGX-202, as the FDA may require additional functional data, which could delay the timeline for pivotal trials.
Market Competition Concerns: 5. Potential Market Risks: The introduction of Eylea biosimilars could impact the market dynamics for RGX-314, raising concerns about competitive pressures in the ophthalmology space.
RGNX FAQs
How does RGNX typically perform around its earnings report dates?
Is REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RGNX Earning Call Sentiment
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
RGNX.O
-3.23%Positive
The earnings call summary shows mixed signals. Financial performance is stable, with cash to fund operations into 2026, but the upsized public offering is a negative indicator. R&D expenses have decreased, which could be seen positively. The Q&A session reveals management's optimism and confidence in product durability and upcoming data, but lacks clarity on biosimilar impact. No strong catalysts like partnerships or guidance changes are present. Overall, the sentiment is balanced, leading to a neutral prediction.
